Mizuho Securities analyst Mara Goldstein downgraded TCR2 Therapeutics (TCRR – Research Report) to a Hold today and set a price target of $1.72. The company’s shares closed today at $1.42.
Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Arcus Biosciences. According to TipRanks, Goldstein has an average return of -4.8% and a 31.52% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for TCR2 Therapeutics with a $3.62 average price target, implying a 154.93% upside from current levels. In a report released today, EF Hutton also reiterated a Hold rating on the stock with a $2.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on TCR2 Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $30.59 million. In comparison, last year the company had a GAAP net loss of $26.24 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Read More on TCRR:
- TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch
